Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with Its Fair Share of Oncological Pitfalls

Overview

Journal World J Nucl Med

Publisher Thieme

Specialty Nuclear Medicine

Date 2024 Jun 27

PMID 38933068

Authors

Akram Al-Ibraheem

Affiliations

Soon will be listed here.

Citing Articles

First Clinical Experience of Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls.

Al-Ibraheem A, Abdlkadir A, Al-Rasheed U, Al-Adhami D, Istatieh F, Anwar F Diagnostics (Basel). 2025; 15(2.

PMID: 39857102 PMC: 11764383. DOI: 10.3390/diagnostics15020218.

References

Bentestuen M, Al-Obaydi N, Zacho H . FAPI-avid nonmalignant PET/CT findings: An expedited systematic review. Semin Nucl Med. 2023; 53(5):694-705. DOI: 10.1053/j.semnuclmed.2023.02.001. View

Qin C, Song Y, Cai W, Lan X . Dimeric FAPI with potential for tumor theranostics. Am J Nucl Med Mol Imaging. 2022; 11(6):537-541. PMC: 8727879. View

Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel F, Haberkorn U . FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. Radiology. 2023; 306(2):e220749. DOI: 10.1148/radiol.220749. View

Al-Ibraheem A, Alyasjeen S, Abdlkadir A, Abu Sheikha A . [Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [Ga]Ga-DOTATOC PET/CT missed. Eur J Nucl Med Mol Imaging. 2023; 50(13):4112-4113. DOI: 10.1007/s00259-023-06348-4. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Pijl J, Nienhuis P, Kwee T, Glaudemans A, Slart R, Gormsen L . Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation. Semin Nucl Med. 2021; 51(6):633-645. DOI: 10.1053/j.semnuclmed.2021.06.008. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Al-Ibraheem A, Zimmermann R, Abdlkadir A, Herrmann K . Radiotheranostics Global Market and Future Developments. Semin Nucl Med. 2024; 54(4):622-633. DOI: 10.1053/j.semnuclmed.2024.02.003. View

Al-Ibraheem A, Abdlkadir A, Alalawi H, Badarneh M . 68 Ga-FAPI PET/CT Imaging : Unveiling the Hidden Pitfalls. Clin Nucl Med. 2023; 48(11):965-966. DOI: 10.1097/RLU.0000000000004802. View

10.

Hicks R, Roselt P, Kallur K, Tothill R, Mileshkin L . FAPI PET/CT: Will It End the Hegemony of F-FDG in Oncology?. J Nucl Med. 2020; 62(3):296-302. DOI: 10.2967/jnumed.120.256271. View

11.

Al-Ibraheem A, Al-Qasem S, El Khaldi M, Amarin R . 68 Ga-FAPI PET/CT Provides a Clear Picture of a Klatskin Tumor That 18 F-FDG PET/CT Missed. Clin Nucl Med. 2023; 48(6):e313-e315. DOI: 10.1097/RLU.0000000000004652. View

12.

Treglia G, Albano D . FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: "watch it like a hawk" or "one swallow does not make a summer"?. Eur J Nucl Med Mol Imaging. 2023; 50(7):1848-1850. PMC: 9986035. DOI: 10.1007/s00259-023-06179-3. View

13.

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J . Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021; 20(1):131. PMC: 8504100. DOI: 10.1186/s12943-021-01428-1. View

14.

Kessler L, Ferdinandus J, Hirmas N, Zarrad F, Nader M, Kersting D . Pitfalls and Common Findings in Ga-FAPI PET: A Pictorial Analysis. J Nucl Med. 2021; 63(6):890-896. PMC: 9157730. DOI: 10.2967/jnumed.121.262808. View